Supriya Lifescience Ltd - SUPRIYA LIFESCI. Share Price

Sector: Pharmaceuticals | ISIN: INE07RO01027
₹ 381.70 (1.34%) icon18 May, 2024, 12:00:00 AM
Open
₹ 379.45
Prev. Close
₹ 376.65
Turnover(lac)
₹ 0.00
Day's High
₹ 382.00
Day's Low
₹ 376.30
52 Wk High
₹ 424.00
52 Wk Low
₹ 233.30
Book Value
₹ 97.12
Face Value
₹ 2.00
Mkt. Cap (Cr.)
₹ 3,072.03
P/E
25.48
EPS
14.96
Div. Yield
0.16

Supriya Lifescience Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 5/18/2024 12:00:00 AM

    ₹ 381.7 5.05 1.34
  • Open
  • ₹ 379.45
  • Prev. Close
  • ₹ 376.65
  • Turnover(Lac.)
  • ₹ 0
  • Day's High
  • ₹ 382
  • Day's Low
  • ₹ 376.3
  • 52 Week's High
  • ₹ 424
  • 52 Week's Low
  • ₹ 233.3
  • Book Value
  • ₹ 97.12
  • Face Value
  • ₹ 2
  • Mkt Cap (₹ Cr.)
  • 3,072.03
  • P/E
  • 25.48
  • EPS
  • 14.96
  • Divi. Yield
  • 0.16

Supriya Lifescience Ltd Corporate Actions

30 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

30 Jan , 2024

12:00 AM

27 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

27 Oct , 2023

12:00 AM

04 Sep , 2023

12:00 AM

AGM

Announcement date: 04 Sep , 2023

View Details

26 May , 2023

12:00 AM

Dividend

Dividend amount: 0.6
Announcement date: 26 May , 2023

View Details

27 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

27 Jul , 2023

12:00 AM

19 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

04 Sep , 2023

12:00 AM

BookCloser

View Details

No Record Found


Supriya Lifescience Ltd News and Update

No Record Found

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Supriya Lifescience Ltd SHAREHOLDING SNAPSHOT
20 May , 2024 | 03:10 AM

PROMOTER - TOTAL68.30%

Indian: 68.30%

Foreign: 0%

NON-PROMOTER - TOTAL 31.70%

Institutions: 10.66%

Non-Institutions: 21.04%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Supriya Lifescience Ltd FINANCIALS

View Profit & Loss Graph

Supriya Lifescience Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Supriya Lifescience Ltd

  • Satish Waman Wagh
  • Chairman & Managing Director
  • Smita Satish Wagh
  • Whole-time Director
  • Soloni Satish Wagh
  • Whole-time Director
  • Shivani Satish Wagh
  • Whole-time Director
  • Balasahab Gulabrao Sawant
  • Whole-time Director
  • Kedar Shankar Karmarkar
  • Independent Director
  • Bhairav Manojbhai Chokshi
  • Independent Director
  • Dileep Kumar Jain
  • Independent Director
  • Dinesh N Modi
  • Independent Director
  • Neelam Yashpal Arora
  • Independent Director
  • Shweta Shivdhari Singh
  • Company Sec. & Compli. Officer
  • Manoj Deo Dorlikar
  • Whole-time Director

Summary

The company was incorporated as Supriya Lifescience Limited on 26 March 2008 upon the conversion of M/s Supriya Chemicals,a partnership firm, into a public limited company.The company commenced operations on 01 April 2008.The company is engaged in manufacturing and export of active pharmaceutical ingredients(APIs).The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development. As of 31 March 2021,the company have niche product offerings of 39 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.The company have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-55% and 65-70%, respectively,of the API exports from India, between Fiscal 2017 and 2020.The company is among the largest exporters of Salbutamol Sulphate from India in Fiscal 2020 in terms of volume.The companys products are approved by various international regulatory authorities such as USFDA, EUGMP, EDQM, SFDA NMPA, ANVISA, KFDA, PMDA, TGA and Taiwan FDA. As of 31 March 2021, the company have filed 11 active DMFs with USFDA and seven active CEPs with EDQM, for API products in therapeutic areas such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.The companys business operations are supported by a modern manufacturing facility located in Parshuram... Read More


Reports by Supriya Lifescience Ltd


Reports by Supriya Lifescience Ltd

Company FAQ

No Record Found